122 related articles for article (PubMed ID: 37598659)
1. Adherence to and persistence with adjuvant hormone therapy, healthcare utilization, and healthcare costs among older women with breast cancer: A population-based longitudinal cohort study.
Zheng D; Thomas J
J Geriatr Oncol; 2023 Nov; 14(8):101599. PubMed ID: 37598659
[TBL] [Abstract][Full Text] [Related]
2. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer.
Zheng D; Thomas J
Breast Cancer Res Treat; 2023 Aug; 201(1):89-104. PubMed ID: 37326766
[TBL] [Abstract][Full Text] [Related]
3. Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications.
Axon DR; Vaffis S; Chinthammit C; Lott BE; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
J Manag Care Spec Pharm; 2020 Dec; 26(12):1529-1537. PubMed ID: 33251989
[No Abstract] [Full Text] [Related]
4. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
5. Association between medication adherence and non-drug healthcare utilisation and costs: a retrospective longitudinal cohort study among US women age 65 and older.
Ma S; Shepard DS; Ritter GA; Martell RE; Thomas C
BMJ Open; 2021 Dec; 11(12):e052146. PubMed ID: 34876428
[TBL] [Abstract][Full Text] [Related]
6. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
Ta JT; Sullivan SD; Tung A; Oliveri D; Gillard P; Devine B
J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730
[No Abstract] [Full Text] [Related]
7. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Dashputre AA; Gatwood KS; Gatwood J
J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Observational Real-Word Analysis of the Adherence, Healthcare Resource Consumption and Costs in Patients Treated with Bisoprolol/Perindopril as Single-Pill or Free Combination.
Masi S; Kobalava Z; Veronesi C; Giacomini E; Degli Esposti L; Tsioufis K
Adv Ther; 2024 Jan; 41(1):182-197. PubMed ID: 37864626
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Corral M; DeYoung K; Kong AM
BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
[TBL] [Abstract][Full Text] [Related]
10. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
11. Potentially inappropriate medication use and associated healthcare utilization and costs among older adults with colorectal, breast, and prostate cancers.
Feng X; Higa GM; Safarudin F; Sambamoorthi U; Tan X
J Geriatr Oncol; 2019 Sep; 10(5):698-704. PubMed ID: 30772191
[TBL] [Abstract][Full Text] [Related]
12. Healthcare costs and utilization associated with pain among breast cancer survivors: a propensity score matched cohort study using SEER-Medicare data.
Lakkad M; Martin B; Li C; Harrington S; Dayer L; Painter JT
J Cancer Surviv; 2023 Aug; 17(4):917-950. PubMed ID: 36369622
[TBL] [Abstract][Full Text] [Related]
13. Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
Kangethe A; Polson M; Lord TC; Evangelatos T; Oglesby A
J Manag Care Spec Pharm; 2019 Jan; 25(1):88-93. PubMed ID: 30589631
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy use among Appalachian breast cancer survivors.
Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
[TBL] [Abstract][Full Text] [Related]
15. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
[TBL] [Abstract][Full Text] [Related]
16. Associations between statin adherence level, health care costs, and utilization.
Zhao Y; Zabriski S; Bertram C
J Manag Care Spec Pharm; 2014 Jul; 20(7):703-13. PubMed ID: 24967523
[TBL] [Abstract][Full Text] [Related]
17. Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: adherence, persistence, healthcare utilization and costs.
Machnicki G; Ong SH; Chen W; Wei ZJ; Kahler KH
Curr Med Res Opin; 2015 Dec; 31(12):2287-96. PubMed ID: 26397178
[TBL] [Abstract][Full Text] [Related]
18. Effect of the ExactCare medication care management model on adherence, health care utilization, and costs.
Shetty KD; Chen AY; Rose AJ; Liu HH
J Manag Care Spec Pharm; 2021 May; 27(5):574-585. PubMed ID: 33560167
[No Abstract] [Full Text] [Related]
19. Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.
Rocque GB; Williams CP; Kenzik KM; Jackson BE; Azuero A; Halilova KI; Ingram SA; Pisu M; Forero A; Bhatia S
Cancer; 2018 Nov; 124(21):4231-4240. PubMed ID: 30317547
[TBL] [Abstract][Full Text] [Related]
20. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
